Literature DB >> 18626627

Natriuretic peptides in acute pulmonary embolism: a systematic review.

Rodrigo Cavallazzi1, Abhilash Nair, Tajender Vasu, Paul E Marik.   

Abstract

BACKGROUND: Patients with pulmonary embolism (PE) have a high risk of death, and it is important to recognize factors associated with higher mortality. Recently, several biomarkers have been studied for risk stratification in patients with PE.
OBJECTIVES: Evaluate the available evidence on (a) the accuracy of brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) for the diagnosis of right ventricular dysfunction and (b) their value as a prognostic factor of all-cause in-hospital or short-term mortality in patients with PE. DATA SOURCES: MEDLINE, Embase, and citation review of relevant primary and review articles. SELECTION CRITERIA: We selected studies evaluating the accuracy of BNP or NT-proBNP for the diagnosis of right ventricular dysfunction. We also selected studies that reported data on BNP or NT-proBNP as a predictor of short-term mortality in patients with PE.
RESULTS: Sixteen studies met our inclusion criteria. The pooled diagnostic odds ratio for the diagnosis of right ventricular dysfunction in pulmonary embolism was 39.45 (95% CI; 15.54-100.12) and 24.73 (95% CI 2.02-302.37) for BNP and NT-proBNP, respectively. The pooled odds ratio for all-cause in-hospital or short-term mortality was 6 (95% CI 1.31-27.43; p: 0.021) and 16.12 (95% CI 3.1-83.68; p: 0.001) for BNP (cutoff: 100 pg/ml) and NT-proBNP (cutoff: 600 ng/L), respectively.
CONCLUSION: The results of this meta-analysis indicate that BNP and NT-proBNP are associated with the diagnosis of right ventricular dysfunction (RVD) in patients with an acute PE and are significant predictors of all-cause in-hospital or short-term mortality in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626627     DOI: 10.1007/s00134-008-1214-5

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  46 in total

Review 1.  The fatty acid transport function of fatty acid-binding proteins.

Authors:  J Storch; A E Thumser
Journal:  Biochim Biophys Acta       Date:  2000-06-26

2.  Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism.

Authors:  Igor I Tulevski; Marye ten Wolde; Dirk J van Veldhuisen; Jasper W M Mulder; Ernst E van der Wall; Harry R Büller; Barbara J M Mulder
Journal:  Int J Cardiol       Date:  2006-06-30       Impact factor: 4.164

3.  Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism.

Authors:  David G Kiely; Norman S Kennedy; Omar Pirzada; Sheila A Batchelor; Allan D Struthers; Brian J Lipworth
Journal:  Respir Med       Date:  2005-10       Impact factor: 3.415

4.  Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism.

Authors:  Anna Kaczyñska; Maurice M A L Pelsers; Anna Bochowicz; Maciej Kostrubiec; Jan F C Glatz; Piotr Pruszczyk
Journal:  Clin Chim Acta       Date:  2006-05-15       Impact factor: 3.786

5.  Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism.

Authors:  Nils Kucher; Gert Printzen; Tanja Doernhoefer; Stephan Windecker; Bernhard Meier; Otto Martin Hess
Journal:  Circulation       Date:  2003-03-24       Impact factor: 29.690

6.  Brain natriuretic peptide in hemodynamically stable acute pulmonary embolism.

Authors:  M Söhne; M Ten Wolde; F Boomsma; J B Reitsma; J D Douketis; H R Büller
Journal:  J Thromb Haemost       Date:  2005-12-23       Impact factor: 5.824

7.  Biomarker-based risk assessment model in acute pulmonary embolism.

Authors:  Maciej Kostrubiec; Piotr Pruszczyk; Anna Bochowicz; Ryszard Pacho; Marcin Szulc; Anna Kaczynska; Grzegorz Styczynski; Agnieszka Kuch-Wocial; Piotr Abramczyk; Zbigniew Bartoszewicz; Hanna Berent; Krystyna Kuczynska
Journal:  Eur Heart J       Date:  2005-05-23       Impact factor: 29.983

8.  Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism.

Authors:  Damien Logeart; Lucien Lecuyer; Gabriel Thabut; Jean-Yves Tabet; Jean-Michel Tartière; Christophe Chavelas; François Bonnin; Jean-Louis Stievenart; Alain Cohen Solal
Journal:  Intensive Care Med       Date:  2006-12-13       Impact factor: 17.440

9.  Correlation between cardiac biomarkers and right ventricular enlargement on chest CT in non massive pulmonary embolism.

Authors:  Nicolas Vuilleumier; Marc Righini; Arnaud Perrier; Antoine Rosset; Natacha Turck; Jean-Charles Sanchez; Henri Bounameaux; Grégoire Le Gal; Noury Mensi; Denis Hochstrasser
Journal:  Thromb Res       Date:  2007-08-22       Impact factor: 3.944

Review 10.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  BMJ       Date:  2003-01-04
View more
  16 in total

1.  Clinical, historical and diagnostic findings associated with right ventricular dysfunction in patients with central and non-massive pulmonary embolism.

Authors:  Domenico Rendina; Silvana De Bonis; Giovanni Gallotta; Vincenzo Piedimonte; Giuseppe Mossetti; Gianpaolo De Filippo; Francesca Farina; Giuseppe Vargas; Maria Rosaria Barbella; Alfredo Postiglione; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2009-11-25       Impact factor: 3.397

2.  Management of pulmonary embolism with rheolytic thrombectomy.

Authors:  Lisa Ferrigno; Robert Bloch; Judson Threlkeld; Thomas Demlow; Raman Kansal; Riyad Karmy-Jones
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

3.  Rapid on-site evaluation of routine biochemical parameters to predict right ventricular dysfunction in and the prognosis of patients with acute pulmonary embolism upon admission to the emergency room.

Authors:  Dong Jia; Fan Liu; Qin Zhang; Guang-Qiao Zeng; Xue-Lian Li; Gang Hou
Journal:  J Clin Lab Anal       Date:  2017-11-21       Impact factor: 2.352

4.  Acute pulmonary embolism with electrocardiagraphic changes mimicking acute coronary syndrome: a case report and literature review.

Authors:  Fei Wang; Jian-Qiang Kang; Shu-Yan Chen; Gen-Fa Wang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 5.  Emergent surgical pulmonary embolectomy in a pregnant woman: case report and literature review.

Authors:  Giovanni Saeed; Michael Möller; Jörg Neuzner; Rainer Gradaus; Werner Stein; Uwe Langebrake; Thomas Dimpfl; Meradjoddin Matin; Ali Peivandi
Journal:  Tex Heart Inst J       Date:  2014-04-01

6.  MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.

Authors:  Lars Heining; Christian Giesa; Santiago Ewig
Journal:  Lung       Date:  2016-01-09       Impact factor: 2.584

Review 7.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

8.  MR-proADM and MR-proANP levels in patients with acute pulmonary embolism.

Authors:  Önsel Öner; Figen Deveci; Selda Telo; Mutlu Kuluöztürk; Mehmet Balin
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

9.  B-type natriuretic peptide as a predictor of outcome in a general intensive care unit.

Authors:  P Grassi; C Calderan; M C Vassallo; D Cageggi; E Stenner; B Biasioli; G Berlot
Journal:  HSR Proc Intensive Care Cardiovasc Anesth       Date:  2011

Review 10.  Prognostic stratification of acute pulmonary embolism: focus on clinical aspects, imaging, and biomarkers.

Authors:  Luca Masotti; Marc Righini; Nicolas Vuilleumier; Fabio Antonelli; Giancarlo Landini; Roberto Cappelli; Patrick Ray
Journal:  Vasc Health Risk Manag       Date:  2009-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.